相关实验视频

Updated: Jul 29, 2025

Implantation of Total Artificial Heart in Congenital Heart Disease

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

心脏药物在 ACHD 心血管医学心血管医学

Magalie Ladouceur^1,2, Estibaliz Valdeolmillos^3,4, Clément Karsenty^5,6

¹Adult Congenital Heart Disease Medico-Surgical Unit, European Georges Pompidou Hospital, 75015 Paris, France.

Journal of cardiovascular development and disease

|May 26, 2023

概括

成人先天性心脏病 (ACHD) 的药物治疗通常是经验性的,因为数据有限. 本综述探讨了当前的心脏药物使用,证据缺口,以及在不断增长的ACHD人口中需要更好的治疗策略.

科学领域:

心脏病学心脏病学
药理学药理学是一个学科.
成年人的先天性心脏病

背景情况:

成人先天性心脏病 (ACHD) 患者数量正在增加,这是由于改善的儿科护理和干预措施.
这一群人面临着终身护理需求和晚期心血管并发症的发病率上升,如心力衰竭和心律失常.
目前对ACHD的药物治疗在很大程度上是支持性的,缺乏正式的指导方针,通常依赖于经验方法.

研究的目的:

审查成人先天性心脏病 (ACHD) 中心脏药物治疗的现状.
识别ACHD患者药物治疗的理由,现有证据和知识差距.
突出进一步研究的需要,以优化治疗结果和生活质量.

主要方法:

对现有研究和关于心脏药物使用在ACHD中的指导方针的文献综述.
对ACHD常见心血管并发症的药物治疗方法的分析.
确定缺乏可靠的临床数据和基于证据的建议的领域.

主要成果:

在ACHD中,药物治疗主要是支持性的,结构性问题往往需要干预或手术治疗.
对于许多用于ACHD的心脏药物,存在重大知识差距和有限的临床数据.
随着ACHD人口的老龄化,心血管并发症的管理面临着独特的挑战.

结论:

更好地了解心脏药物使用在ACHD是提高患者的结果和生活质量至关重要的.
进一步的研究是必不可少的,以制定基于证据的药物治疗在ACHD的指导方针.
解决日益增长的ACHD人口的特定需求需要专门研究有效的治疗策略.

关键词:

成年人的先天性心脏病.药物治疗是药物治疗.心脏衰竭是因为心脏衰竭.药理疗法是一种药理疗法.试验试验试验试验

更多相关视频

Fetal Mouse Cardiovascular Imaging Using a High-frequency Ultrasound 30/45MHZ System

Fetal Mouse Cardiovascular Imaging Using a High-frequency Ultrasound 30/45MHZ System

Published on: May 5, 2018

Analysis of Congenital Heart Defects in Mouse Embryos Using Qualitative and Quantitative Histological Methods

Analysis of Congenital Heart Defects in Mouse Embryos Using Qualitative and Quantitative Histological Methods

Published on: March 10, 2020

相关概念视频

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...